Stockreport

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

Cartesian Therapeutics, Inc.  (RNAC) 
PDF Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase [Read more]